Boston Scientific (BSX) to Update on Three co-Primary Endpoints for PREVAIL at ACoC
Tweet Send to a FriendGet Alerts BSX Hot Sheet
Trade BSX Now!
Boston Scientific Corp. (NYSE: BSX) PREVAIL clinical trial results will be presented in a Late-Breaking Clinical Trial presentation at the 62nd Annual Scientific Sessions of the American College of Cardiology, and will include all three co-primary endpoints that evaluate safety and efficacy of the WATCHMAN® Left Atrial Appendage (LAA) Closure device in patients with nonvalvular atrial fibrillation versus long-term warfarin therapy. This will be the first time all three co-primary endpoints in the PREVAIL study will be presented.
The preliminary results of the PREVAIL Trial will be presented on March 9 in San Francisco, California by David R. Holmes Jr., M.D., Mayo Clinic, Rochester, Minn., at 9:10 a.m. PT, in the Moscone Center, South, Esplanade Ballroom.
Specifically, Dr. Holmes will present preliminary analysis on the following co-primary endpoints:
* Acute (7-day) occurrence of death, ischemic stroke, systemic embolism and procedure or device related complications requiring major cardiovascular or endovascular intervention
* Comparison of composite of stroke, systemic embolism, and cardiovascular/unexplained death at 18 months follow-up
* Comparison of ischemic stroke or systemic embolism occurring from greater than 7 days post randomization to 18 months follow-up
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The preliminary results of the PREVAIL Trial will be presented on March 9 in San Francisco, California by David R. Holmes Jr., M.D., Mayo Clinic, Rochester, Minn., at 9:10 a.m. PT, in the Moscone Center, South, Esplanade Ballroom.
Specifically, Dr. Holmes will present preliminary analysis on the following co-primary endpoints:
* Acute (7-day) occurrence of death, ischemic stroke, systemic embolism and procedure or device related complications requiring major cardiovascular or endovascular intervention
* Comparison of composite of stroke, systemic embolism, and cardiovascular/unexplained death at 18 months follow-up
* Comparison of ischemic stroke or systemic embolism occurring from greater than 7 days post randomization to 18 months follow-up
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Sanofi (SNY), Regeneron (REGN) Report Publication of Positive Dupilumab Phase 2a Data
- Sprint (S) Granted Waiver From SoftBank to Consider DISH (DISH) Bid
- OSI Systems (OSIS) Unit Issued Notice of Proposed Debarment from U.S. DHS
Create E-mail Alert Related Categories
Corporate News, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
